Vertex commences Phase 3 Study of VX-659 for CF
Vertex Pharmaceuticals affirmed initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis…
Read More...
Read More...